Product Information
ALAHIST PE 2-7.5 MG TABLET is a generic product labeled by Poly Pharmaceuticals, Inc., priced at $0.6569 per EA under NDC 50991078890. Its NADAC has been published 198 times since Dec 21, 2022.
Strength
2; 7.5 mg/1; mg/1
Manufacturer
Poly Pharmaceuticals, Inc.NDC
50991078890
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DEXBROMPHENIRAMINE MALEATE; PHENYLEPHRINE HYDROCHLORIDEApproval Type
OTC MONOGRAPH DRUG
FDA Application
M012On Market Since
8/24/2020
Pharmacological Classes
Price Statistics
The NADAC for ALAHIST PE 2-7.5 MG TABLET has been published 198 times since Dec 21, 2022, and over the history we have for it it has risen 2.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6569 per EA |
|---|---|
| All-time high | $0.6661 (Apr 15, 2026) |
| All-time low | $0.6206 (Apr 17, 2024) |
| 52-week high | $0.6661 |
| 52-week low | $0.6539 |
| Median price | $0.6590 |
| Average price | $0.6512 |
| Largest weekly change | +7.2% (May 22, 2024) |
| Weeks tracked | 198 |
| Tracking since | Dec 21, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Dexbrompheniramine Maleate, Phenylephrine Hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Poly Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Dexbrompheniramine Maleate, Phenylephrine Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
alpha-1 Adrenergic Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ALAHIST PE 2-7.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ALAHIST PE 2-7.5 MG TABLET, manufactured by Poly Pharmaceuticals, Inc., is $0.6569 per EA (NDC 50991078890), effective Sep 30, 2026.
How has the price of ALAHIST PE 2-7.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for ALAHIST PE 2-7.5 MG TABLET has risen 2.6%. It has been tracked across 198 weekly CMS publications since Dec 21, 2022.
What are the highest and lowest recorded NADAC prices for ALAHIST PE 2-7.5 MG TABLET?
Since Dec 21, 2022, the NADAC for ALAHIST PE 2-7.5 MG TABLET has ranged from a low of $0.6206 (Apr 17, 2024) to a high of $0.6661 (Apr 15, 2026), with a median of $0.6590 per EA.
Are there cheaper alternatives to ALAHIST PE 2-7.5 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of ALAHIST PE 2-7.5 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ALAHIST PE 2-7.5 MG TABLET?
ALAHIST PE 2-7.5 MG TABLET (NDC 50991078890) is labeled by Poly Pharmaceuticals, Inc., and CMS classifies it as a generic product.